51 results about "Ketone concentration" patented technology

S-Beta-hydroxybutyric acid compositions for oral delivery are effective in rapidly raising blood ketone levels without causing acute acidosis or gastrointestinal (GI) distress when consumed in sufficiently dilute form and / or as a gel or suspension. By limiting added beta-hydroxybutyrate salts containing alkali or alkaline earth metal ions, beta-hydroxybutyric acid solutions, gels, or suspensions can deliver exogenous ketone bodies without significantly altering electrolyte balance. Although aqueous beta-hydroxybutyric acid solutions are moderately acidic with a pH of about 3.5 to 4, when diluted with sufficient water, the water acts as a pseudo buffering agent that offsets otherwise harsh acidic effects when consumed orally. Gels and suspensions can also ameliorate acidic effects by partially encapsulating the beta-hydroxybutyric acid. Beta-hydroxybutyric acid can be pure S-beta-hydroxybutyric acid or a non-racemic mixture enriched with S-beta-hydroxybutyric acid relative to R-beta-hydroxybutyric acid.

Compositions for delivering ketone bodies to a subject include one or more beta-hydroxybutyrate salts, one or more acetoacetate salts, beta-hydroxybutyric acid, and optionally acetoacetic acid. The compositions may optionally include one or more ketone body esters, such as one or more beta-hydroxybutyrate esters and / or one or more acetoacetate esters. An example composition contains about 2% to about 98% on a molar basis of the one or more beta-hydroxybutyrate salts and the one or more acetoacetate salts, about 2% to about 98% on a molar basis of the beta-hydroxybutyrate free acid and optionally the acetoacetate free acid, and optionally about 2% to about 98% on a molar basis of one or more ketone body esters.

The invention relates to the technical field of glucometers, and discloses an intelligent multifunctional glucometer supporting data cloud storage and remote analysis, which comprises hardware, detection, data processing, wireless communication, a cloud server platform and an interactive terminal module to form a complete data closed loop. The hardware module is composed of an upper shell and a lower shell which are clamped, and the upper shell is provided with a detection port, an operation button and anti-skid lines. The detection module is integrated with an electrochemical sensor array and can synchronously detect blood glucose, uric acid, ketone body and blood fat. The data processing unit processes data in real time to generate a health report, and the wireless communication module supports multi-mode communication and encrypted transmission. The cloud platform stores data and outputs suggestions through machine learning, and the interactive terminal supports biological recognition and voice broadcast. The modules cooperate to realize multi-index detection, cloud analysis and intelligent interaction. The system has the advantages of multi-index synchronous detection, data security intelligent analysis and convenient interaction, and supports data cloud storage and remote analysis.

The invention provides an energy complementation guidance method for endurance sports and related electronic equipment, and the energy complementation guidance method comprises the steps: receiving measured glucose data of a first time period from a glucose sensor, the measured glucose data reflecting the glucose level of an endurance athlete wearing the glucose sensor; receiving measured ketone body data from the ketone body sensor for a first period of time, the measured ketone body data reflecting a ketone body level of the endurance athlete wearing the ketone body sensor; predicting an energy result based on the measured glucose data and the measured ketone body data, the energy result representing whether the endurance athlete is energy depleted after a second time period after the first time period; and transmitting energy complementation information based on the energy result. Therefore, the accuracy of identifying the energy complementation opportunity can be improved.

This invention discloses a respiratory mask with multi-parameter detection capabilities, comprising: a main body of the respiratory mask and multiple sensors connected thereto; the multiple sensors include at least a carbon dioxide sensor, a pH sensor, and a ketone body sensor, used to detect the carbon dioxide concentration, pH value, and ketone body value in the patient's exhaled gas, respectively; the main body of the respiratory mask is provided with a one-way inlet valve and a one-way outlet valve, the one-way outlet valve being connected to one end of the outlet pipe to guide the exhaled gas to the outlet pipe; the carbon dioxide sensor and the ketone body sensor are both connected to one end of the outlet pipe; the main body of the respiratory mask is provided with a condensation structure to condense water vapor in the exhaled gas into condensate, and the condensate is transported to the pH sensor for detection through a condensate collection pipe. This invention can simultaneously detect multiple parameters, is simple and convenient to operate, and has high sensitivity, which helps to improve the accuracy of disease diagnosis.

Provided is a novel prophylactic and / or therapeutic agent useful for preventing and / or treating diseases of which symptoms are relieved or ameliorated by an increase in blood ketone body concentration.　The present invention pertains to a medicine for preventing and / or treating diseases of which symptoms are relieved or ameliorated by an increase in blood ketone body concentration, the medicine comprising a therapeutically effective amount of (R)-2-[3-[[N-(benzoxazol-2-yl)-N-3-(4-methoxyphenoxy)propyl]aminomethyl]phenoxy]butyric acid, a salt thereof, or a solvate thereof.

The application provides a ketone body powder transfer device and belongs to the technical field of medical apparatuses. The grabbing assembly comprises a pressing column and a U-shaped elastic plate. The pressing column is slidingly connected to the inner wall of the grabber body near the top end. One end of the U-shaped elastic plate is fixedly connected to the outer wall of the grabber body near the bottom end. A weakened groove is formed in the middle of the U-shaped elastic plate near the outer wall of the grabber body. A second sliding groove is formed in the outer wall of the grabber body near the other end of the U-shaped elastic plate. A third sliding groove is formed in the inner wall of the grabber body near the bottom end of the second sliding groove. The grabbing assembly can form a grabbing space to grab the ketone body powder, avoid the waste of ketone body powder caused by spillover during the transfer process, is simple to operate, and can prevent the contamination of the bottle opening caused by the hand shaking of the experimenter.

The invention provides a method for estimating an energy supply proportion based on glucose and ketone bodies and a related method and equipment, and the method for estimating the energy supply proportion comprises the steps: building a metabolic model based on a target metabolic pathway, the metabolic model being used for representing the relationship among a plurality of target metabolites related to the target metabolic pathway; a measured glucose concentration and a measured ketone body concentration are obtained, the measured glucose concentration and the measured ketone body concentration represent the glucose concentration and the ketone body concentration of blood in different tissues where the target metabolic pathway is distributed respectively, and the multiple target metabolites comprise glucose and ketone bodies of the blood; estimating a concentration of a first portion of the plurality of target metabolites based on the measured glucose concentration, the measured ketone body concentration, and a metabolic model; an energy supply ratio of glucose and fat is determined based on the concentration of the first portion of the plurality of target metabolites. Therefore, the convenience of estimating the energy supply proportion can be improved.

An object of the present application is to provide a new composition for promoting ketogenesis. According to the present application, there is provided a composition for promoting ketogenesis containing one or two or more amino acids selected from the group consisting of citrulline, leucine, cysteine, taurine, glutamine and aspartic acid. The composition of the present application can further contain either or both of a medium-chain fatty acid and a medium-chain fatty acid ester.

Compositions and methods for administering ketone bodies to a subject include a ketone body or ketone body precursor complexed with or coupled to at least one amino acid. The compositions and methods cause one or more of: weight loss, weight maintenance, reduced blood glucose level, maintenance of blood glucose level, increased muscle and physical performance, enhanced metabolic and cellular repair, improved detoxification and gut health, targeted bioavailability, sustained release and controlled absorption, increased metabolic efficiency, enhanced cellular uptake, minimized side effects, multifunctional therapeutics, improved focus, improved energy, improved cognitive function, improved mental acuity, treatment of traumatic brain injury, treatment of diabetes, treatment of neurological disorder, treatment of cancer, treatment of inflammatory condition, appetite suppression, anti-aging effects, anti-glycation effects, treatment of epilepsy, treatment of depression, improved performance, improved muscle mass, improved motor function, increased strength, increased metabolism, increased fat loss, increased fat oxidation, improved body composition, and improved mood.

The present disclosure provides a method for producing views related to data on glucose and ketone bodies and a related system. The method comprises receiving analyte data from an analyte sensor; determining, on the basis of the received analyte data, analyte concentration data comprising glucose concentration data and ketone body concentration data; and displaying, on the basis of the analyte concentration data, on a display unit a plurality of views comprising a first view, wherein the first view comprises a graphical display generated on the basis of the analyte concentration data over a time period, the graphical display comprises a region representing the distribution of a plurality of data points, and the position of each data point is determined by the glucose concentration and the ketone body concentration at the same time. The present disclosure enables an observer to more conveniently analyze energy metabolism and is friendlier to the observer.

This invention belongs to the field of biochemistry, and specifically relates to a β-hydroxybutyrylation modification biomarker of OXCT1 and its application in the diagnosis and treatment of ketoacidosis. A biomarker for ketoacidosis is a β-hydroxybutyrylation modification of lysine 421 on the OXCT1 protein. This biomarker is used in the diagnosis of ketoacidosis by detecting the Kbhb modification level of OXCT1 and the expression level of OXCT1 in various ketone body utilizing organs, serving as an auxiliary diagnostic indicator for ketoacidosis. In the treatment of ketoacidosis, the Kbhb modification of lysine 421 on the OXCT1 protein is used as a therapeutic target for patients with ketoacidosis, and can be applied to the treatment of ketoacidosis to reduce blood ketone levels. This invention proposes a new diagnostic and treatment method for ketoacidosis. The biomarker can also be used to prepare diagnostic reagents or kits for ketoacidosis.

The invention provides a compound which is a compound as shown in a formula I or a tautomer, a stereoisomer, a hydrate, a solvate, a pharmaceutically acceptable salt or a prodrug of the compound as shown in the formula I. OXCT1 protein can be effectively combined, and the dual-enzyme activity inhibition effect is achieved. Specifically, the compound not only can inhibit the activity of ketolytic enzyme of OXCT1, but also can inhibit the activity of succinyltransferase of OXCT1. Therefore, the compound can effectively prevent and / or treat cancers highly expressing OXCT1.

The invention provides a processing device based on analyte concentration data and a related method. The processing device comprises an acquisition module and a processing module, the acquisition module is used for receiving first analyte data related to glucose concentration and second analyte data related to ketone body concentration, wherein the first analyte data and the second analyte data are obtained by continuously monitoring at least two analytes of a target object through the analyte sensor. The processing module is configured to acquire analyte concentration data including glucose concentration data and ketone body concentration data based on the first analyte data and the second analyte data, acquire at least one feature set based on the analyte concentration data over a time period, and determine target information including at least energy information based on the at least one feature set, the energy information is the relationship between the estimated intake energy and consumed energy of the target object, the intake energy is the energy of the intake carbohydrate, and the consumed energy is the consumed energy. As a result, it is possible to improve the convenience of evaluating the relationship between intake and consumption of carbohydrates.

Provided is use of leuconostoc mesenteroides and / or metabolites thereof in preparing a composition for reducing body fat, suppressing appetite, promoting the ketone body level or regulating fasting blood glucose, wherein the leuconostoc mesenteroides is leuconostoc mesenteroides subsp. mesenteroides with the preservation number of DSM34443.

The subject disclosure provides compositions for reducing serum cholesterol and / or triglyceride levels in subjects. These compositions can comprise racemic β-hydroxybutyrate or D-β-hydroxybutyrate, optionally in the acid form, physiologically compatible salts of racemic β-hydroxybutyrate or D-β-hydroxybutyrate, esters of D-β-hydroxybutyrate, oligomers of D-β-hydroxybutyrate containing from 2 to 20 or more monomeric units in either linear or cyclic form, racemic 1,3 butandiol or R-1,3 butandiol alone and can be, optionally, administered in conjunction with a low fat diet to a subject. Alternatively, compositions comprising racemic β-hydroxybutyrate or D-β-hydroxybutyrate, optionally in the acid form, physiologically compatible salts of racemic β-hydroxybutyrate or D-β-hydroxybutyrate, esters of D-β-hydroxybutyrate, oligomers of D-β-hydroxybutyrate containing from 2 to 20 or more monomeric units in either linear or cyclic form, racemic 1,3 butandiol, R-1,3 butandiol or combinations thereof can be formulated as nutritional supplements (also referred to as nutritional compositions) or incorporated into therapeutic compositions containing a) anti-hypertensive agents; b) anti-inflammatory agents; c) glucose lowering agents; or d) anti-lipemic agents) which are administered to a subject, optionally in combination with a low fat diet, in order to cause a reduction or lowering of: serum cholesterol levels; triglyceride levels; serum glucose levels, serum homocysteine levels, inflammatory proteins (e.g., C reactive protein) and / or hypertension in treated subjects. Alternatively, compositions disclosed herein can be administered alone, or in combination with other therapeutic agents to prevent or reverse vascular disease.

The purpose of the present invention is to provide a novel enzyme for ketone body measurement that, unlike 3-hydroxybutyrate dehydrogenase, does not require NAD, which has low thermal stability, and therefore does not require a substance for reoxidizing NADH. The novel enzyme according to the present invention is a 3-hydroxybutyrate oxidase that is derived from a microorganism selected from the group consisting of microorganisms belonging to the genus Achromobacter, microorganisms belonging to the genus Pseudomonas, microorganisms belonging to the genus Trypanosoma, and microorganisms belonging to the genus Nocardia and has a physicochemical property of catalyzing a reaction for producing hydrogen peroxide by acting on D-3-hydroxybutyric acid, or is a 3-hydroxybutyrate oxidase that comprises an amino acid sequence represented by SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, or SEQ ID NO: 7, or a sequence similar thereto.

This application discloses an implantable dual-channel monitoring sensor and its fabrication method. The sensor includes a substrate and an electrode assembly, a sensing component, and a functional component disposed on the substrate. The sensing component includes a glucose sensing layer and a ketone body sensing layer, and the functional component includes a first functional film layer and a second functional film layer. The electrode assembly includes a first working electrode, a second working electrode, a reference electrode, and a counter electrode. The first working electrode has a glucose sensing layer disposed on it, and the second working electrode has a ketone body sensing layer disposed on it. The first functional film layer encapsulates the glucose sensing layer, and the second functional film layer encapsulates the ketone body sensing layer. This application enables dual-channel collaborative continuous monitoring and seamless integration of the two monitoring data. Furthermore, this implantable dual-channel monitoring sensor has low design cost, simple manufacturing process, and mass production advantages.

Methods of efficaciously increasing ketone body levels in a human bloodstream, thereby supporting various health benefits associated with ketosis, including improved metabolic health and enhanced endurance performance. Compositions including mixtures of esters that are used by a user's body to create ketosis related molecules in the blood stream are disclosed. Methods of forming the mixtures and exemplary starting materials are disclosed. Compositions may comprise mixtures of ketone body analog esters designed for nutritional supplementation. Compositions include esters such as 3-Hydroxy-3-methylbutyl 3-oxobutanoate and(S)-3-Hydroxybutyl 3-oxobutanoate, which mimic the physiological effects of natural ketosis. The present invention includes methods for synthesizing compositions through reactions involving 1,3-Butanediol, 3-Hydroxy-3-methylbutanol, and various acids in the presence of enzyme systems. Resulting esters enhance energy metabolism, support muscle recovery, promote cognitive function, and aid in weight management. Compositions may be tailored by adjusting reactant ratios and reaction conditions, offering flexibility in achieving desired ester profiles.

A risk calculator is needed that consists of factors capable of better predicting or assessing the risk of premature death from any cause. [Solution] A method and system are disclosed for determining a subject's Metabolic Vulnerability Index (MVX) score using at least one defined risk mathematical model. The method includes evaluating various biomarkers to distinguish between different health risks. In one embodiment, the method includes evaluating biomarkers to determine the relative risk of early all-cause mortality. The model may include NMR-derived measurements of GlycA, S-HDLP, branched-chain amino acids (BCAAs), ketone bodies, total serum proteins, and citrates in at least one biological sample of the subject.

An organoleptically acceptable composition containing a ketone body or a ketone body precursor including a hydroxybutyrate ester and a flavouring is provided and gives improved palatability and user adherence to the intended dose regime. The flavouring may be a bitter flavouring and the composition may further contain an adsorbent for the ketone such that on ingestion, the bitterness of the composition may be masked. The composition may be in the form of a solid, gel or liquid and provides increased blood ketone levels and may be used in therapy or in treating muscle impairment or fatigue.

Systems, methods, and devices predict pharmacokinetic parameters following administration of a formulation, such as a medium-chain triglyceride (MCT). The method includes generating training data indicating human metabolism outcomes of the formulation. The training data includes stomach emptying parameters, a digestion rate, an absorption constant, or a conversion rate with a training target variable being ketone concentration or plasma free fatty acid concentration. The method also includes training a physiologically based biopharmaceutics (PBB) model with the training data and using the PBB model to predict, using the patient data, at least one of a target plasma free fatty acid concentration or a target ketone concentration. Furthermore, as part of a parameter sensitivity analysis of the PBB model, the method varies input parameters of the training data against a simulated mean plasma free fatty acid profile or a simulated mean ketone plasma profile.

The invention provides a compound which is a compound as shown in a formula I or a tautomer, a stereoisomer, a hydrate, a solvate, a pharmaceutically acceptable salt or a prodrug of the compound as shown in the formula I. The compound can be effectively combined with OXCT1 protein and exerts a dual enzyme activity inhibition effect. Specifically, the compound not only can inhibit the activity of ketolytic enzyme of OXCT1, but also can inhibit the activity of succinyltransferase of OXCT1. Therefore, the compound can effectively prevent and / or treat cancers highly expressing OXCT1.

The utility model belongs to the technical field of testing devices, and particularly relates to a device for testing the concentration of ketone in the milk of dairy cows in the perinatal period, which comprises a ketone body detector, and one surface of the ketone body detector is provided with an interface; a rectangular groove is formed in the side, close to the connector, of the ketone body detector, a rectangular block is slidably connected into the rectangular groove through a first spring, a connecting rod is fixedly installed on one side of the rectangular block, and a baffle is fixedly installed at the end, away from the rectangular block, of the connecting rod; through the designed structure, quick closing and protection are realized when the interface is not used, and the time of direct exposure of the interface is reduced, so that the situation that pollutants such as dust, impurities and water enter the interface to affect the accuracy of subsequent detection is reduced.

A method and composition for increasing or maintaining ketone body levels and improving metabolic functions, and use thereof. The method comprises administering to a subject in need thereof a composition comprising an effective amount of 3-acetoxybutyric acid or a pharmaceutically acceptable salt thereof, an ester thereof, or a derivative thereof. The composition further comprises an effective amount of 3-hydroxybutyric acid or a pharmaceutically acceptable salt thereof, an ester thereof, or a derivative thereof. Also provided is use of the composition in the preparation of a dietary supplement, food, beverage, or animal feed.

S-Beta-hydroxybutyric acid compositions for oral delivery are effective in rapidly raising blood ketone levels without causing acute acidosis or gastrointestinal (GI) distress when consumed in sufficiently dilute form and / or as a gel or suspension. By limiting added beta-hydroxybutyrate salts containing alkali or alkaline earth metal ions, beta-hydroxybutyric acid solutions, gels, or suspensions can deliver exogenous ketone bodies without significantly altering electrolyte balance. Although aqueous beta-hydroxybutyric acid solutions are moderately acidic with a pH of about 3.5 to 4, when diluted with sufficient water, the water acts as a pseudo buffering agent that offsets otherwise harsh acidic effects when consumed orally. Gels and suspensions can also ameliorate acidic effects by partially encapsulating the beta-hydroxybutyric acid. Beta-hydroxybutyric acid can be pure S-beta-hydroxybutyric acid or a non-racemic mixture enriched with S-beta-hydroxybutyric acid relative to R-beta-hydroxybutyric acid.

The purpose of the present disclosure is to provide a novel production method with which it is possible to produce a ketone body of diacetone glucose and diacetone allose in a relatively simple manner.　The present disclosure is a method for producing a solution containing a ketone body of diacetone glucose. The production method includes the following first to fourth steps.　The first step is a step for generating a first solution in which diacetone glucose is dissolved in an acetic acid ester.　The second step is a step in which a first aqueous solution containing an oxidizing agent is mixed with the first solution, and the diacetone glucose is oxidized into a ketone body thereof in the presence of an oxidation catalyst.　The third step is a step for separating a second solution after the oxidation reaction obtained in the second step into an organic solution and a second aqueous solution.　The fourth step is a step for obtaining the organic solution.

Disclosed herein are compositions that include a combination of: (1) a non-xanthine CNS stimulant or nootropic; (2) a ketone body or ketone body precursor, such as beta-hydroxybutyrate (BHB) salt, BHB ester, BHB acid, acetoacetate salt, acetoacetate ester, acetoacetic acid, 1,3-butanediol, medium chain fatty acid, or ester of medium chain fatty acid; and (3) optionally a dietetically or pharmaceutically acceptable carrier. The composition may include a vasodilator. The composition may include a short or medium chain fatty acid or ester thereof in addition to or instead of the ketone body or ketone body precursor. The composition can provide enhanced cognitive flexibility, improved sustained attention, improved working memory, and neuroprotection in a mammal. The composition can also beneficially increase resting energy expenditure (resting metabolic rate), particularly when in a state of ketosis, enhancing fat loss principally through ketosis while promoting muscle formation and maintenance, as well as modulating lethargy / lightheadedness when entering a ketogenic state.

Use of a ketone body and a ketone body ester for preserving glycogen and / or protein, thereby reducing muscle breakdown and improving endurance during exercise and promoting muscle recovery following exercise. Also for retarding muscle wasting in aging and disease. (R)-3-hydroxybutyl (R)-3-hydroxybutyrate for use in reducing muscle glycogen and protein breakdown during exercise or decreasing muscle wasting in aging and disease. Certain esters of hydroxybutyrate monomers, particularly a monoester of D-β-hydroxybutyrate with R-1,3-butanediol or with glycerol to reduce muscle breakdown and aid muscle recovery after exercise or retard muscle wasting. Compositions containing the ketone bodies or ketone body esters are also described.

The present disclosure provides esters and amides between known pharmaceutical, supplements, nutritional sugars, or nutritional compounds and ketone bodies and ketone body precursors with an enhanced bioavailability to mitigate adverse effects such as liver and kidney stress, gastrointestinal irritation, skin irritation, ulcers, and bleeding.